Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.81% |
| 2 | Technology | 15.51% |
| 3 | Consumer Discretionary | 11.84% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DBTX
3701
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
| $75K | ﹤0.01% |
36,394
+4,094
| +13% | +$12.5K |
|
|
HEPA
3702
DELISTED
Hepion Pharmaceuticals
HEPA
| $74K | ﹤0.01% |
246
+14
| +6% | +$5.92K |
|
|
MOGU
3703
MOGU Inc
MOGU
$15.3M
| $74K | ﹤0.01% |
30,057
+1,100
| +4% | +$2.61K |
|
|
VSTA
3704
DELISTED
Vasta Platform
VSTA
| $74K | ﹤0.01% |
18,500
-1,500
| -8% | -$6.88K |
|
|
FUSN
3705
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $74K | ﹤0.01% |
23,500
+6,700
| +40% | +$16.7K |
|
|
AMAM
3706
DELISTED
Ambrx Biopharma Inc
AMAM
| $74K | ﹤0.01% |
32,500
-31,500
| -49% | -$36K |
|
|
CNTB
3707
Connect Biopharma Holdings
CNTB
$147M
| $73K | ﹤0.01% |
83,900
+600
| +0.7% | +$494 |
|
|
MDRR
3708
Medalist Diversified Inc
MDRR
$18.7M
| $73K | ﹤0.01% |
6,519
-1,606
| -20% | -$19.7K |
|
|
SYBX
3709
DELISTED
Synlogic
SYBX
| $73K | ﹤0.01% |
6,427
-1,280
| -17% | -$15.6K |
|
|
ONCR
3710
DELISTED
Oncorus, Inc.
ONCR
| $73K | ﹤0.01% |
286,936
+77,403
| +37% | +$44K |
|
3711
Creative Realities
CREX
$39.3M
| $72K | ﹤0.01% |
41,433
-4,900
| -11% | -$8.96K |
|
|
JG
3712
Aurora Mobile
JG
$31.3M
| $72K | ﹤0.01% |
5,615
-290
| -5% | -$5.15K |
|
3713
US Gold Corp
USAU
$252M
| $72K | ﹤0.01% |
+15,100
| New | +$61K |
|
3714
Atlantic American Corp
AAME
$30.2M
| $71K | ﹤0.01% |
30,500
-1,100
| -3% | -$3.04K |
|
3715
electroCore
ECOR
$84.7M
| $71K | ﹤0.01% |
18,471
+1,143
| +7% | +$5.32K |
|
3716
IGC Pharma
IGC
$30.7M
| $71K | ﹤0.01% |
222,011
-98,889
| -31% | -$40.3K |
|
|
NCTY
3717
The9 Ltd
NCTY
$61.1M
| $71K | ﹤0.01% |
12,529
-4,720
| -27% | -$35.6K |
|
3718
Dolphin Entertainment
DLPN
$14.8M
| $70K | ﹤0.01% |
19,200
-700
| -4% | -$3.59K |
|
3719
Imunon
IMNN
$6.77M
| $70K | ﹤0.01% |
3,988
-115
| -3% | -$2.21K |
|
|
KORE
3720
DELISTED
KORE Group Holdings
KORE
| $70K | ﹤0.01% |
11,120
+2,820
| +34% | +$32.4K |
|
|
NEXI
3721
DELISTED
NexImmune, Inc. Common Stock
NEXI
| $70K | ﹤0.01% |
11,588
+11,080
| +2,181% | +$138K |
|
3722
Context Therapeutics
CNTX
$46.5M
| $69K | ﹤0.01% |
105,300
-25,288
| -19% | -$27.2K |
|
3723
Farmmi Inc
FAMI
$4.96M
| $69K | ﹤0.01% |
1,784
+214
| +14% | +$11K |
|
3724
Quantum-Si Incorporated
QSI
$172M
| $69K | ﹤0.01% |
+37,556
| New | +$96.8K |
|
3725
Spire Global
SPIR
$540M
| $69K | ﹤0.01% |
8,950
-4,195
| -32% | -$41K |
|
Similar funds
Jim Simons's Q4 2022 Portfolio in Review
As of Q4 2022, Jim Simons held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Jim Simons added most to Apple in Q4 2022, an estimated $839M increase.
- Jim Simons's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Jim Simons fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Jim Simons's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Jim Simons opened 626 new positions and closed 524 in Q4 2022.
- Jim Simons's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.